Icahn School of Medicine at Mount Sinai

Adam Vincek

Michael H Ohlmeyer

Ming-Ming Zhou

Nilesh Zaware

Michael Katz

Efrat Eliyahu

Anthony Fargnoli

The present disclosure relates generally to the use of sphingolipid-metabolizing proteins to mitigate or minimize tissue damage resulting from injury or from disease, for example, pulmonary arterial hypertension (PAH) when the sphingolipid-metabolizing protein is delivered via expression from an Anc80 vector.

Anc80 encoding sphingolipid-metabolizing proteins for mitigating disease-induced tissue damage

Cyclic vinylogous amides of Formula I are disclosed The compounds are useful for treating diseases that arise from inappropriate activity of proteins containing an acetyl-lysine. The compositions comprise a genus of cyclic vinylogous amides that are inhibitors of bromodomain.

Cyclic vinylogous amides as bromodomain inhibitors

Cyclic vinylogous amides of Formula I are disclosed  The compounds are useful for treating diseases that arise from inappropriate activity of proteins containing an acetyl-lysine. The compositions comprise a genus of cyclic vinylogous amides that are inhibitors of bromodomain.

Growing community of inventors

Tarrytown, NY, United States of America

Adam Vincek